Fennec Pharmaceuticals (FENC) EBIAT (2016 - 2025)
Fennec Pharmaceuticals (FENC) has disclosed EBIAT for 15 consecutive years, with -$637000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT rose 88.89% year-over-year to -$637000.0, compared with a TTM value of -$6.9 million through Sep 2025, down 512.44%, and an annual FY2024 reading of -$436000.0, up 97.28% over the prior year.
- EBIAT was -$637000.0 for Q3 2025 at Fennec Pharmaceuticals, up from -$3.2 million in the prior quarter.
- Across five years, EBIAT topped out at $12.8 million in Q1 2024 and bottomed at -$6.9 million in Q4 2022.
- Average EBIAT over 5 years is -$2.9 million, with a median of -$3.9 million recorded in 2021.
- Peak annual rise in EBIAT hit 312.11% in 2024, while the deepest fall reached 207.18% in 2024.
- Year by year, EBIAT stood at -$4.1 million in 2021, then crashed by 67.8% to -$6.9 million in 2022, then surged by 61.1% to -$2.7 million in 2023, then grew by 25.99% to -$2.0 million in 2024, then soared by 67.91% to -$637000.0 in 2025.
- Business Quant data shows EBIAT for FENC at -$637000.0 in Q3 2025, -$3.2 million in Q2 2025, and -$1.2 million in Q1 2025.